Alkermes plc. (NASDAQ: ALKS) To Present A Poster About Nemvaleukin Alfa at 2022 ASCO Gastrointestinal Cancers Symposium

Alkermes plc. (NASDAQ: ALKS) has announced intentions to present a poster in connection to nemvaleukin alfa, its novel, experimental, engineering interleukin-2 variant immunotherapy, at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.

Alkermes to present at 2022 ASCO GI

Ulka Vaishampayan, Internal Medicine Professor in the hematology/oncology division at the University of Michigan, will make the presentation titled, “Nemvaleukin alfa combination therapy for gastrointestinal (GI) cancers: preclinical evidence and clinical data from the ARTISTRY-1 trial.” The poster and the pre-recorded presentation are accessible on the ASCO GI virtual conference platform from January 20, 2022.  

Clinical data from ARTISTRY-1, a phase 1/2 study assessing the efficacy and tolerability profile of nemvaleukin intravenous administration as a single agent and as a combination with pembrolizumab (KEYTRUDA®), as well as preclinical findings from the nemvaleukin study in combination with proprietary agents in GI cancers, are highlighted in the poster.

Nemvaleukin’s selectivity widens tumor-killing immune cells

Nemvaleukin is a proprietary, experimental, engineered fusion protein made up of altered interleukin-2 (IL-2) with the strong affinity IL-2 alpha receptor chain. It is intended to selectively broaden tumor-killing immune cells while avoiding immunosuppressive cells’ stimulation through base pairing to the medium-affinity IL-2 response element. Nemvaleukin’s selectivity is intended to make use of current IL-2 therapy’s demonstrated antitumor benefits while addressing some of its drawbacks.

ARTISTRY is an Alkermes-sponsored clinical study testing nemvaleukin as possible cancer immunotherapy. The ARTISTRY initiative consists of various clinical studies testing subcutaneous and intravenous doses of nemvaleukin in individuals with aggressive solid tumors, both as a single agent and in conjunction with the anti-PD-1 treatment KEYTRUDA® (pembrolizumab). ARTISTRY-1, ARTISTRY-2, ARTISTRY-3, ARTISTRY-6, and ARTISTRY-7 are all ongoing trials in the ARTISTRY program.

Alkermes is a global, fully integrated biopharmaceutical firm that develops novel medications in the disciplines of neurology and cancer. The firm has a pipeline of pharmaceutical product candidates currently in studies for neurodegenerative illnesses and cancer and a portfolio of patented commercial medications focusing on schizophrenia, bipolar I disorder, and addiction.